eIF1AY inhibitors represent a class of compounds that specifically target and inhibit the activity of the eukaryotic translation initiation factor 1A (eIF1A), which is essential in the initiation phase of protein synthesis. eIF1A plays a crucial role in stabilizing the binding of the initiator tRNA to the small ribosomal subunit and promoting the proper scanning of the messenger RNA (mRNA) for the start codon. By inhibiting eIF1A, these compounds disrupt the normal initiation process, leading to a decrease in overall protein synthesis. This inhibition can have significant effects on cellular processes, as protein synthesis is fundamental to cell growth, division, and response to environmental stimuli.
The mechanism of action of eIF1AY inhibitors involves binding to specific sites on the eIF1A protein, thereby preventing its interaction with the ribosomal subunits and other initiation factors. This binding can induce conformational changes in eIF1A, rendering it incapable of performing its function in the initiation complex. The development and study of eIF1AY inhibitors have provided valuable insights into the molecular dynamics of translation initiation and the regulatory mechanisms controlling protein synthesis. These compounds have also been used as tools in research to dissect the roles of eIF1A in various cellular pathways and to understand the broader implications of translational control in cellular physiology. The study of eIF1AY inhibitors continues to be a dynamic field, contributing to our understanding of the intricate processes that govern gene expression at the translational level.
SEE ALSO...
Items 1 to 10 of 16 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Salubrinal | 405060-95-9 | sc-202332 sc-202332A | 1 mg 5 mg | $34.00 $104.00 | 87 | |
Salubrinal inhibits eIF2α dephosphorylation, leading to prolonged phosphorylation, which reduces translation initiation. | ||||||
Guanabenz HCl | 23113-43-1 | sc-507500 | 100 mg | $246.00 | ||
Guanabenz reduces eIF2α phosphorylation by activating the eIF2α phosphatase, PP1, allowing translation to proceed normally. | ||||||
GSK 2606414 | 1337531-36-8 | sc-490182 sc-490182A | 5 mg 25 mg | $163.00 $572.00 | ||
GSK2606414 inhibits the activity of PERK, a kinase that phosphorylates eIF2α, reducing eIF2α phosphorylation levels. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin indirectly affects eIF2α by causing DNA damage, triggering the integrated stress response and eIF2α phosphorylation. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin induces ER stress, activating PERK and leading to eIF2α phosphorylation, thereby inhibiting protein synthesis. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Etoposide causes DNA damage, which could lead to a cellular stress response, potentially diverting cellular resources from RNAi pathways and thus down-regulating eIF2C2. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
By acting as a pyrimidine analog, 5-Fluorouracil might disrupt nucleotide metabolism. This disruption could indirectly affect RNAi components by hampering RNA synthesis, leading to decreased eIF2C2 levels. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib inhibits the proteasome, affecting protein turnover. This can disrupt the balance of cellular proteins, potentially decreasing the stability or synthesis of eIF2C2. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D hinders RNA synthesis by intercalating DNA. This can lead to a general down-regulation of RNA-derived processes, which might include a decrease in eIF2C2 levels. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
By inhibiting protein synthesis, Cycloheximide might halt the production of new eIF2C2 molecules, leading to a net decrease in eIF2C2 as existing proteins degrade. | ||||||